多发性骨髓瘤中的双抗原靶向 T 细胞免疫治疗:规避肿瘤异质性和预防抗原逃逸 Dual-antigen-targeting T-cell immunotherapies in MM: circumventing tumor heterogeneity and preventing antigen escape. PubMed 2026/05/07 发表BloodQ1 · IF 23.9(JCR 2025) 靶点:CD38靶点:BCMA靶点:GPRC5D技术:CAR-T技术:双特异性抗体多发性骨髓瘤
探索 BCMA/GPRC5D 后的治疗格局:塞利尼索、硼替佐米与地塞米松在五重难治性多发性骨髓瘤序贯免疫治疗失败后的疗效——多中心分析 Navigating the Post-BCMA/GPRC5D Landscape: Efficacy of Selinexor, Bortezomib, and Dexamethasone After Sequential Immunotherapy Failure in Penta-Refrac PubMed 2026/03/31 发表Am J HematolQ1 · IF 9.4(JCR 2025) 靶点:CD38靶点:BCMA靶点:GPRC5D技术:CAR-T多发性骨髓瘤地区:欧洲
ide-cel 早期复发后 BCMA 靶向双特异性抗体治疗结局不佳:一项法国真实世界研究 Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study. PubMed 2026/02/24 发表Blood AdvQ1 · IF 7.7(JCR 2025) 靶点:CD38靶点:BCMA靶点:GPRC5D技术:CAR-T技术:双特异性抗体多发性骨髓瘤
双特异性抗体在多发性骨髓瘤中的演进 The evolution of bispecific antibodies in multiple myeloma. PubMed 2026/02/01 发表Chin Clin OncolQ3 · IF 2.7(JCR 2025) 靶点:CD20靶点:CD38靶点:BCMA技术:双特异性抗体多发性骨髓瘤B细胞淋巴瘤淋巴瘤
SOHO 最新进展与后续问题 | 骨髓瘤早期复发的治疗:非 CAR-T 细胞 SOHO State of the Art Updates and Next Questions | Treatment of Myeloma Early Relapse: Non-CAR T Cell. PubMed 2025/10/04 发表Clin Lymphoma Myeloma LeukQ1 · IF 4.1(JCR 2025) 靶点:CD38靶点:BCMA靶点:GPRC5D技术:CAR-T技术:双特异性抗体多发性骨髓瘤淋巴瘤白血病
多发性骨髓瘤的新型免疫靶点:生物学意义与治疗潜力 Novel immunotargets in multiple myeloma: biological relevance and therapeutic potential. PubMed 2025/07/01 发表Biomark ResQ1 · IF 14.6(JCR 2025) 靶点:CD38靶点:CD70靶点:BCMA技术:双特异性抗体多发性骨髓瘤地区:欧洲
靶向 BCMA 或 GPRC5D 的双特异性抗体在 CAR-T 细胞治疗后复发多发性骨髓瘤中高度有效 Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy. PubMed 2024/12/05 发表Blood Cancer JQ1 · IF 13.8(JCR 2025) 靶点:CD38靶点:BCMA靶点:GPRC5D技术:CAR-T技术:双特异性抗体多发性骨髓瘤
超越骨髓:髓外多发性骨髓瘤肿瘤综合下一代测序的见解 Beyond the marrow: insights from comprehensive next-generation sequencing of extramedullary multiple myeloma tumors. PubMed 2024/03/16 发表LeukemiaQ1 · IF 8.8(JCR 2025) 靶点:CD38靶点:CD70靶点:GPRC5D技术:NK 细胞多发性骨髓瘤白血病
多发性骨髓瘤中 CAR-T 或 BiTE 治疗的患者选择:每位患者应选择哪种治疗? Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient? PubMed 2022/06/07 发表J Hematol OncolQ1 · IF 47.8(JCR 2025) 靶点:CD38靶点:GPRC5D靶点:FcRH5技术:CAR-T技术:双特异性抗体多发性骨髓瘤
多发性骨髓瘤靶向免疫治疗新前沿的潜力抗原 Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma. PubMed 2021/12/06 发表Cancers (Basel)Q2 · IF 4.8(JCR 2025) 靶点:CD38靶点:BCMA靶点:GPRC5D技术:CAR-T技术:双特异性抗体多发性骨髓瘤